Despite the generally durable responses to CAR-T therapies in relapsed or refractory large B-cell lymphoma, some patients do still progress and data following progression are limited. These retrospective studies presented at ASH 2022 assessed progression-free survival and overall survival in patients receiving salvage treatment post-CAR-T failure.
This study investigated the safety and efficacy of axi-cel in 9 patients with PCNSL and SCNSL. The authors reported no increased risk of high-grade ICANS, cerebral oedema, or other neurologic events; Complete response rate was 86%.
Real-world evidence continues to be made available of CAR-T in the clinic. A series of studies into real-world effectiveness of CAR-T therapies were presented at ASH 2022. Here we present two notable abstracts:
This retrospective study aimed to investigate the effects of bendamustine on CAR T-cell production and clinical outcomes.
